NCT04280081View on ClinicalTrials.gov

A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

March 16, 2020

Primary Completion Date

March 25, 2021

Study Completion Date

November 30, 2027

Conditions
Solid TumorMedullary Thyroid Cancer
Interventions
DRUG

Selpercatinib

Administered orally

Trial Locations (13)

100142

Beijing Cancer Hospital, Beijing

130000

Jilin Cancer Hospital, Changchun

200030

Shanghai Chest Hospital, Shanghai

200032

Fudan University Shanghai Cancer Center, Shanghai

200120

Shanghai East Hospital, Shanghai

250013

Jinan Central Hospital, Jinan

300060

Tianjin Medical University Cancer Institute & Hospital, Tianjin

310003

The First Affiliated Hospital, Zhejiang University, Hangzhou

310014

Zhejiang Provincial People's Hospital, Hangzhou

310022

Zhejiang Cancer Hospital, Hangzhou

410013

Hunan Cancer Hospital, Changsha

510120

The First Affiated Hospital Of Guangzhou Medical University, Guangzhou

510515

Southern Medical University Nanfang Hospital, Guangzhou

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT04280081 - A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation | Biotech Hunter | Biotech Hunter